SCHEMBL1466085

SCHEMBL1466085

CC(C)P(Cc1cccc(CP(C(C)C)C(C)C)c1)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.38
SLC6A2 P23975 2/20 0.38
MAOA P21397 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CYP2A6 P11509 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
GRIN2D O15399 2/20 0.37
GRIN3B O60391 2/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2A Q12879 2/20 0.37
GRIN2B Q13224 2/20 0.37
GRIN2C Q14957 2/20 0.37
GRIN3A Q8TCU5 2/20 0.37
PNMT P11086 1/20 0.36
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15946908 0.86 TAAR1 (0.32) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL9453231 0.83 TAAR1 (0.44) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL14822593 0.79 TAAR1 (0.31) TAAR1SLC6A2SLC6A3HTR2AHTR2B
SCHEMBL11763961 0.79 HTR2A (0.42) SIGMAR1CYP2A6GRIN2DGRIN2AGRIN2B
SCHEMBL14810256 0.73 TAAR1 (0.35) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL4449680 0.72 MEN1 (0.36) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL11760566 0.71 HTR2A (0.37) CYP2A6GRIN2DGRIN2AGRIN2BGRIN2C
SCHEMBL3630782 0.70 GABRA1 (0.34) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL11764978 0.70 CYP1A2 (0.36) SIGMAR1CYP2D6KMT2A
SCHEMBL1465458 0.70 KCNH2 (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113896607-B Olefin oligomerization process using a catalyst comprising a chromium complex having a phosphacycle-containing ligand 陶氏环球技术有限责任公司 2024-04-16 CN disclosed
US-20220176363-A1 PROCESS FOR OLIGOMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2022-06-09 US disclosed
CN-107548385-B Olefin oligomerization process using catalyst comprising chromium complex with phosphacycle-containing ligand 陶氏环球技术有限责任公司 2022-01-21 CN disclosed
US-20210129125-A1 PROCESS FOR OLIGOMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2021-05-06 US disclosed
US-10981156-B2 Chromium complex and catalyst therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2021-04-20 US disclosed
US-10919031-B2 Process for oligomerization DOW GLOBAL TECHNOLOGIES LLC (US) 2021-02-16 US disclosed
US-20200338542-A1 PROCESS FOR OLIGOMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2020-10-29 US disclosed
US-10702861-B2 Process for oligomerization DOW GLOBAL TECHNOLOGIES LLC (US) 2020-07-07 US disclosed
EP-3653299-A1 CHROMIUM COMPLEX WITH A PHOSPHACYCLE-CONTAINING LIGAND AND OLEFIN OLIGOMERISATION CATALYST THEREFROM Dow Global Technologies LLC (US) 2020-05-20 EP disclosed
EP-3653300-A1 OLEFIN OLIGOMERIZATION PROCESS WITH A CATALYST COMPRISING A CHROMIUM COMPLEX WITH A PHOSPHACYCLE-CONTAINING LIGAND Dow Global Technologies LLC (US) 2020-05-20 EP disclosed
CN-101730656-B Method for the production of hydrogen from ammonia borane 卡娜塔化学技术股份有限公司 2017-05-03 CN disclosed
US-20140228573-A1 Zirconium Containing Hydrosilylation Catalysts and Compositions Containing the Catalysts DOW CORNING CORPORATION (US) 2014-08-14 US disclosed
US-20140228573-A1 Zirconium Containing Hydrosilylation Catalysts and Compositions Containing the Catalysts DOW CORNING CORPORATION (US) 2014-08-14 US disclosed
US-8518368-B2 Method for the production of hydrogen from ammonia borane KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2013-08-27 US disclosed
US-8518368-B2 Method for the production of hydrogen from ammonia borane KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2013-08-27 US disclosed
WO-2013043799-A1 ZIRCONIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS DOW CORNING CORPORATION (US) 2013-03-28 WO disclosed
US-20110070152-A1 METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2011-03-24 US disclosed
US-20110070152-A1 METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2011-03-24 US disclosed
EP-2158154-A1 METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE Kanata Chemical Technologies Inc. (CA) 2010-03-03 EP disclosed
WO-2008141439-A1 METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210129125-A1 PROCESS FOR OLIGOMERIZATION OXER1, NOD1, LIG1 TAAR1 1180/4885SLC6A2 4876/4885MAOA 954/4885
US-20200338542-A1 PROCESS FOR OLIGOMERIZATION OXER1, NOD1, LIG1 TAAR1 1180/4885SLC6A2 4876/4885MAOA 954/4885
US-10919031-B2 Process for oligomerization OXER1, NOD1, LIG1 TAAR1 1180/4885SLC6A2 4876/4885MAOA 954/4885
US-10981156-B2 Chromium complex and catalyst therefrom OXER1, LIG1, PICALM TAAR1 2024/4885SLC6A2 4864/4885MAOA 1915/4885
US-20220176363-A1 PROCESS FOR OLIGOMERIZATION OXER1, NOD1, LIG1 TAAR1 1180/4885SLC6A2 4876/4885MAOA 954/4885
US-20140228573-A1 Zirconium Containing Hydrosilylation Catalysts and Compositions Containing the Catalysts ALG8, ZRANB2, ZKSCAN2 TAAR1 2863/4885SLC6A2 4792/4885MAOA 3510/4885
US-10702861-B2 Process for oligomerization OXER1, NOD1, LIG1 TAAR1 1180/4885SLC6A2 4876/4885MAOA 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.